Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Tern Therapeutics announced its launch Aug. 27, along with closing of a $15 million financing. The company also reported that it had licensed gene therapy candidates RGX-381 and RGX-181 (now design...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
NexThera, of Busan, South Korea, announced July 16 that it had filed an investigational new drug (IND) application with the US FDA for a Phase I/IIa trial of NT-101, an eye drop candidate for wet a...
China’s DP Technology announced July 8 that it would advance DPT0415, a novel small molecule targeting lipoprotein‐associated phospholipase A2 (Lp-PLA2), as a potential oral treatment candidate for...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Ireland-based LEP Biomedical reported April 4 that it had closed a pre-seed funding round of €100 thousand to advance its HyaGuard platform. HyaGuard is a biodegradable, subconjunctival insert desi...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
France’s PulseSight Therapeutics, developing non-viral ophthalmic gene therapies, launched Feb. 28 with an undisclosed seed financing from Pureos Bioventures and ND Capital. A spokeswoman for Pulse...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Enzene Biosciences announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references Lucentis, which is sol...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Celularity and Verséa Ophthalmics announced an exclusive US commercial agreement on July 27. Verséa will distribute Celularity’s Biovance and Biovance 3L for ocular surface disease and ocular surgi...
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.